Trials / Completed
CompletedNCT01292447
A Trial of 2% Lidocaine Gel for Intrauterine Device (IUD) Insertion
A Randomized Controlled Trial of 2% Lidocaine Gel for IUD Insertion
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Women and Infants Hospital of Rhode Island · Academic / Other
- Sex
- Female
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The intrauterine device (IUD) is a long-acting, highly effective, reversible contraceptive that may be underutilized due to fear of pain during insertion. Although providers frequently prescribe non-steroidal anti-inflammatory drugs (NSAIDs) for IUD insertion, there is no evidence for any pain reduction. In fact, no interventions evaluated in randomized controlled trials have been shown to be effective in reducing pain during IUD insertion. While many women tolerate IUD insertion well, others have moderate to severe pain. This double-blind randomized controlled trial of 150 women aims to estimate the efficacy of intracervical 2% lidocaine gel compared to placebo (KY jelly) to reduce IUD insertion pain. Our hypothesis is that women who are treated with 2% lidocaine gel prior to IUD insertion will have reduced pain as measured on a 0 mm to 100 mm Visual Analog Scale (VAS). We will be able to detect a 15 mm difference on the VAS with our sample size. Other data to be collected include information regarding age, BMI, obstetric history, lactation status, time since pregnancy or delivery, last menstrual period, history of cervical conization, anxiety levels, anticipated pain levels, insertion characteristics (time, difficulty, complications), side effects, and satisfaction with pain control. If 2% lidocaine gel is effective, then a viable, easily administered option for pain control will be available to providers and patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 2% lidocaine gel | 120mg lidocaine x 1 |
| DRUG | Placebo gel | Inert gel x 1 |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2011-02-09
- Last updated
- 2020-09-02
- Results posted
- 2020-09-02
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01292447. Inclusion in this directory is not an endorsement.